[EPISODE 24] Dr. David Berkowitz Talks Enzymes, Radiation, And The Lincoln Marathon
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
The complete suite of assays & services needed to detect and characterize responses to SARS-CoV-2.
Bioagylitix delivers rebustdata sets abd comprehensive data interpretation beyond what a typical diagnostic lab can offer
Speak to our scientists to get your testing underway today. Call us directly at +1 919-381-6097 or complete this request form.
As experts in clinical assays, BioAgilytix delivers robust data sets and comprehensive data interpretation beyond what a typical diagnostic lab can offer.
We also offer the breadth of testing needed to determine disease state, characterize antibody response, and assess biomarkers related to SARS-CoV-2, the virus associated with COVID-19.
Our assays are helping the global pharma & biotech community address the immediate threats of COVID-19 with new vaccine and anti-viral therapeutic programs, and also look ahead at how patients with antibodies to SARS-CoV-2 might impact and change clinical trial strategies moving forward.
Robust Data Sets
We specialize in assays for clinical trials, so our results will stand up to stringent regulatory submission requirements.
Our Boston, MA and Durham, NC labs can perform testing under CLIA to support patient enrollment in clinical trials
We’re able to tailor our testing strategies to your unique program, and can support development of de novo assays.
BioAgilytix’s highly specific immune response assays detect IgA, IgM, and IgG antibodies to identify individuals who were infected and have already recovered from COVID-19.
In addition to qualitative assessments, we are also able to provide semi-quantitative measurements (titer) to assess a patient’s relative levels (magnitude of the response) which indicate stage of infection and strength of antibody response.
Emerging data suggests that CRS in patients with severe cases of COVID-19 may cause death. BioAgilytix can apply our validated MSD cytokine/chemokine panels to quantify these biomarkers in patients receiving novel therapeutics for the treatment of COVID-19.
These panels have undergone full bioanalytical validation at BioAgilytix and are already utilized to support a broad range of clinical trials today.
Using our Biacore™ T200 platform, we are also able to assess immune response as well as characterize isotype switching to distinguish fresh infection from later infection and determine antibody affinities to define antibody maturation.
Biacore is available at our European lab in Hamburg, Germany and with it we are able to conduct highly specific analysis with efficient time-to-result.
We’re committed to applying our specialized expertise and proven processes to help our customers test for and understand the impacts of the novel COVID-19 disease. And with fully operational labs, we’re ready to help today..
Tell us a little more about your needs for testing related to SARS-CoV-2 and the associated COVID-19 disease. We’ll get back to you right away to discuss how we can help.